PURPOSE Despite the successes achieved in chronic myeloid leukemia (CML) with tyrosine
kinase inhibitor (TKI) therapy, resistance remains an obstacle. The most common …

Background Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm that harbors
the Philadelphia chromosome. Tyrosine kinase inhibitor (TKI) therapy has dramatically …

Objective This article identifies and evaluates the frequency of mutations in the BCR-ABL1
kinase domain (KD) of chronic myeloid leukemia (CML) patients who showed suboptimal …

Background: Imatinib resistance is commonly associated with the activation of BCR-ABL
signaling in chronic myeloid leukaemia (CML). The activation of Lyn can result in imatinib …

CML is a commonly diagnosed myeloproliferative neoplasm in India. Tyrosine kinase
inhibitors (TKIs) are the current standard of care for management of CML. Mutations in …

BCR‐ABL mutations are associated with resistance to tyrosine kinase inhibitors (TKIs) in
Philadelphia chromosome‐positive leukaemia. The emergence of these mutations in the era …

Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm caused by the BCR::
ABL1 fusion gene, which results from a reciprocal translocation between chromosome 9 and …

Актуальность. Мутации киназного домена гена BCR-ABL наиболее частая причина
резистентности к ингибиторам тирозинкиназ. Цель. Представить данные о …

The development of mutations in the BCR-ABL1 fusion gene transcript causes resistance to
tyrosine kinase inhibitors (TKIs) based therapy in chronic myeloid leukemia (CML). Thereby …

Chronic myelogenous leukemia is a myeloproliferative disorder which is characterized by
malignant transformation of blood progenitor cells. BCR-ABL fusion gene formation after …